David W McCormick1,2, LaTonia Clay Richardson3, Paul R Young3, Laura J Viens3, Carolyn V Gould3, Anne Kimball3,2, Talia Pindyck3, Hannah G Rosenblum3,2, David A Siegel3, Quan M Vu3, Ken Komatsu4, Heather Venkat4,5, John J Openshaw6, Breanna Kawasaki7, Alan J Siniscalchi8, Megan Gumke9, Andrea Leapley9, Melissa Tobin-D'Angelo10, Judy Kauerauf11, Heather Reid11, Kelly White12, Farah S Ahmed13, Gillian Richardson14, Julie Hand14, Kim Kirkey15, Linnea Larson16, Paul Byers17, Ali Garcia18, Mojisola Ojo19, Ariela Zamcheck20, Maura K Lash21, Ellen H Lee21, Kathleen H Reilly21, Erica Wilson22, Sietske de Fijter23, Ozair H Naqvi24, Laurel Harduar-Morano5,25, Anna-Kathryn Burch26, Adele Lewis27, Jonathan Kolsin28, Stephen J Pont28, Bree Barbeau29, Danae Bixler3, Sarah Reagan-Steiner3, Emilia H Koumans. 1. Coronavirus Disease 2019 Response Team yup1@cdc.gov. 2. Epidemic Intelligence Service. 3. Coronavirus Disease 2019 Response Team. 4. Arizona Department of Health Services, Phoenix, Arizona. 5. Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. California Department of Public Health, Sacramento, California. 7. Colorado Department of Public Health and Environment, Denver, Colorado. 8. State of Connecticut Department of Public Health, Hartford, Connecticut. 9. Florida Department of Health, Tallahassee, Florida. 10. Georgia Department of Public Health, Atlanta, Georgia. 11. Illinois Department of Public Health, Springfield, Illinois. 12. Indiana Department of Health, Indianapolis, Indiana. 13. Kansas Department of Health and Environment, Topeka, Kansas. 14. Louisiana Department of Health, Baton Rouge, Louisiana. 15. Michigan Department of Health and Human Services, Lansing, Michigan. 16. Minnesota Department of Health, Saint Paul, Minnesota. 17. Mississippi State Department of Health, Jackson, Mississippi. 18. Nevada Department of Health and Human Services, Carson City, Nevada. 19. New Jersey Department of Health, Trenton, New Jersey. 20. New York State Department of Health, Albany, New York. 21. New York City Department of Health and Mental Hygiene, New York City, New York. 22. North Carolina Department of Health and Human Services, Raleigh, North Carolina. 23. Ohio Department of Health, Columbus, Ohio. 24. Oklahoma State Department of Health, Oklahoma City, Oklahoma. 25. Pennsylvania Department of Health, Harrisburg, Pennsylvania. 26. South Carolina Department of Health and Environmental Control, Columbia, South Carolina. 27. Tennessee Department of Health, Nashville, Tennessee. 28. Texas Department of State Health Services, Austin, Texas. 29. Utah Department of Health, Salt Lake City, Utah.
Abstract
OBJECTIVES: To describe the demographics, clinical characteristics, and hospital course among persons <21 years of age with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated death. METHODS: We conducted a retrospective case series of suspected SARS-CoV-2-associated deaths in the United States in persons <21 years of age during February 12 to July 31, 2020. All states and territories were invited to participate. We abstracted demographic and clinical data, including laboratory and treatment details, from medical records. RESULTS: We included 112 SARS-CoV-2-associated deaths from 25 participating jurisdictions. The median age was 17 years (IQR 8.5-19 years). Most decedents were male (71, 63%), 31 (28%) were Black (non-Hispanic) persons, and 52 (46%) were Hispanic persons. Ninety-six decedents (86%) had at least 1 underlying condition; obesity (42%), asthma (29%), and developmental disorders (22%) were most commonly documented. Among 69 hospitalized decedents, common complications included mechanical ventilation (75%) and acute respiratory failure (82%). The sixteen (14%) decedents who met multisystem inflammatory syndrome in children (MIS-C) criteria were similar in age, sex, and race and/or ethnicity to decedents without MIS-C; 11 of 16 (69%) had at least 1 underlying condition. CONCLUSIONS: SARS-CoV-2-associated deaths among persons <21 years of age occurred predominantly among Black (non-Hispanic) and Hispanic persons, male patients, and older adolescents. The most commonly reported underlying conditions were obesity, asthma, and developmental disorders. Decedents with coronavirus disease 2019 were more likely than those with MIS-C to have underlying medical conditions.
OBJECTIVES: To describe the demographics, clinical characteristics, and hospital course among persons <21 years of age with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated death. METHODS: We conducted a retrospective case series of suspected SARS-CoV-2-associated deaths in the United States in persons <21 years of age during February 12 to July 31, 2020. All states and territories were invited to participate. We abstracted demographic and clinical data, including laboratory and treatment details, from medical records. RESULTS: We included 112 SARS-CoV-2-associated deaths from 25 participating jurisdictions. The median age was 17 years (IQR 8.5-19 years). Most decedents were male (71, 63%), 31 (28%) were Black (non-Hispanic) persons, and 52 (46%) were Hispanic persons. Ninety-six decedents (86%) had at least 1 underlying condition; obesity (42%), asthma (29%), and developmental disorders (22%) were most commonly documented. Among 69 hospitalized decedents, common complications included mechanical ventilation (75%) and acute respiratory failure (82%). The sixteen (14%) decedents who met multisystem inflammatory syndrome in children (MIS-C) criteria were similar in age, sex, and race and/or ethnicity to decedents without MIS-C; 11 of 16 (69%) had at least 1 underlying condition. CONCLUSIONS: SARS-CoV-2-associated deaths among persons <21 years of age occurred predominantly among Black (non-Hispanic) and Hispanic persons, male patients, and older adolescents. The most commonly reported underlying conditions were obesity, asthma, and developmental disorders. Decedents with coronavirus disease 2019 were more likely than those with MIS-C to have underlying medical conditions.
Authors: Madeleine W Sumner; Alicia Kanngiesser; Kosar Lotfali-Khani; Nidhi Lodha; Diane Lorenzetti; Anna L Funk; Stephen B Freedman Journal: Front Pediatr Date: 2022-06-09 Impact factor: 3.569
Authors: Hyunju Lee; Sujin Choi; Ji Young Park; Dae Sun Jo; Ui Yoon Choi; Heayon Lee; Yun Tae Jung; In Hyuk Chung; Young June Choe; Jin Yong Kim; Young-Joon Park; Eun Hwa Choi Journal: J Korean Med Sci Date: 2022-01-03 Impact factor: 2.153
Authors: Mary A King; Renee I Matos; Mitchell T Hamele; Matthew A Borgman; Luke A Zabrocki; Samir K Gadepalli; Ryan C Maves Journal: Chest Date: 2022-01-07 Impact factor: 10.262
Authors: Anna L Funk; Todd A Florin; Nathan Kuppermann; Daniel J Tancredi; Jianling Xie; Kelly Kim; Mark I Neuman; Lilliam Ambroggio; Amy C Plint; Santiago Mintegi; Terry P Klassen; Marina I Salvadori; Richard Malley; Daniel C Payne; Norma-Jean Simon; Adriana Yock-Corrales; Jasmine R Nebhrajani; Pradip P Chaudhari; Kristen A Breslin; Yaron Finkelstein; Carmen Campos; Kelly R Bergmann; Maala Bhatt; Fahd A Ahmad; Michael A Gardiner; Usha R Avva; Nipam P Shah; Laura F Sartori; Vikram J Sabhaney; Kerry Caperell; Nidhya Navanandan; Meredith L Borland; Claudia R Morris; Iker Gangoiti; Viviana Pavlicich; Nirupama Kannikeswaran; Maren M Lunoe; Pedro B Rino; April J Kam; Jonathan C Cherry; Alexander J Rogers; Shu-Ling Chong; Laura Palumbo; Carlos M Angelats; Andrea K Morrison; Maria Y Kwok; Sarah M Becker; Andrew C Dixon; Naveen Poonai; Michelle Eckerle; Muhammad Wassem; Stuart R Dalziel; Stephen B Freedman Journal: JAMA Netw Open Date: 2022-01-04
Authors: Jordana Vaz Hendler; Patricia Miranda do Lago; Gabriel Cardozo Müller; João Carlos Santana; Jefferson Pedro Piva; Liane Esteves Daudt Journal: Braz J Infect Dis Date: 2021-11-10 Impact factor: 1.949